• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
WAM

WAM CAPITAL LIMITED - Discussion

1.63% ! $1.56
Market Cap $0  !
Financial Services Asset Management
Add to My Watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Wam Capital Limited

edit-2 Created with Sketch. New Thread
refresh Created with Sketch. REFRESH
Forum Tag Subject View Poster Comments Created with Sketch. Views Created with Sketch. Likes Created with Sketch. Date Created with Sketch.
refresh Created with Sketch. REFRESH

Featured News

NEWS Are the 'magnificent seven' still worth investing in? Not really
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
Start T rading
Last
$1.56 		Change
0.025(1.63%) 		Mkt cap ! N/A
Open High Low Volume
$1.54 $1.57 $1.54 1.021M

Buyers (Bids)

Vol. Price($)
12057 $1.56
 

Sellers (Offers)

Price($) Vol.
$1.57 2740
Last trade - 16.10pm 03/07/2026 (20 minute delay) ?
WAM (ASX) Chart

Top Stories

GreenTech Metals readies for Munni Munni and Whundo drill programs

GreenTech Metals is on target to commence drilling programs at the Munni Munni and Whundo projects in the West Pilbara in Western Australia.
Pursuit Minerals kicks off drill hole three at Rio Grande Sur lithium project Pursuit Minerals has commenced diamond drilling at priority hole DDH-3 within the Mito tenement at its Rio Grande Sur lithium project.
Expert Exchange: David Sokulsky on AI trade, chip stocks, and where to invest now Carrara Capital CIO David Sokulsky on why he's bullish on AI but cautious on valuations, Nvidia, SK Hynix, and his top trading advice.
OncoSil Medical files for US FDA approval for specialist device OncoSil Medical has hit a key milestone in its plans to commercialise its unique OncoSil device for the treatment of dCCA.
ADVFN appoints Jason Paltrowitz as non-executive director ADVFN Ltd is pleased to announce the appointment of Jason Paltrowitz as a Non-Executive Director. Jason brings more than 20 years of leadership experience across global capital markets, investor relations, exchange services, and corporate advisory.Listen to the HotCopper podcast for in-depth disc...

Featured News

NEWS Are the 'magnificent seven' still worth investing in? Not really
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.